A prospective study on the pathogenesis of catheter-associated bacteriuria in critically ill patients.


Journal

BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981

Informations de publication

Date de publication:
22 03 2021
Historique:
received: 02 12 2020
accepted: 08 03 2021
entrez: 23 3 2021
pubmed: 24 3 2021
medline: 15 12 2021
Statut: epublish

Résumé

Updating the pathogenesis of catheter-associated bacteriuria (CA-bacteriuria) in the intensive care unit (ICU) is needed to adapt prevention strategies. Our aim was to determine whether the main pathway of CA-bacteriuria in ICU patients was endoluminal or exoluminal. In a prospective study, quantitative urine cultures were sampled from catheter sampling sites, collector bags and the catheter outer surface near the meatus from days 1 to 15 after catheterization. The endoluminal pathway was CA-bacteriuria (defined as 10 Of 64 included patients, 20 had CA-bacteriuria. Means of catheterization days and incidence density were 6.81 days and 55.2/1000 catheter-days. Of 26 microorganisms identified, 12 (46.2%) were Gram positive cocci, 8 (30.8%) Gram negative bacilli and 6 yeasts. Three (11.5%) CA-bacteriuria were endoluminal and 23 (88.5%) exoluminal, of which 10 (38.5%) were early and 13 (50%) late. Molecular comparison confirmed culture findings. A quality audit showed good compliance with guidelines. The exoluminal pathway of CA-bacteriuria in ICU patients predominated and surprisingly occurred early despite good implementation of guidelines. This finding should be considered in guidelines for prevention of CA-bacteriuria.

Sections du résumé

BACKGROUND
Updating the pathogenesis of catheter-associated bacteriuria (CA-bacteriuria) in the intensive care unit (ICU) is needed to adapt prevention strategies. Our aim was to determine whether the main pathway of CA-bacteriuria in ICU patients was endoluminal or exoluminal. In a prospective study, quantitative urine cultures were sampled from catheter sampling sites, collector bags and the catheter outer surface near the meatus from days 1 to 15 after catheterization. The endoluminal pathway was CA-bacteriuria (defined as 10
RESULTS
Of 64 included patients, 20 had CA-bacteriuria. Means of catheterization days and incidence density were 6.81 days and 55.2/1000 catheter-days. Of 26 microorganisms identified, 12 (46.2%) were Gram positive cocci, 8 (30.8%) Gram negative bacilli and 6 yeasts. Three (11.5%) CA-bacteriuria were endoluminal and 23 (88.5%) exoluminal, of which 10 (38.5%) were early and 13 (50%) late. Molecular comparison confirmed culture findings. A quality audit showed good compliance with guidelines.
CONCLUSION
The exoluminal pathway of CA-bacteriuria in ICU patients predominated and surprisingly occurred early despite good implementation of guidelines. This finding should be considered in guidelines for prevention of CA-bacteriuria.

Identifiants

pubmed: 33752594
doi: 10.1186/s12866-021-02147-9
pii: 10.1186/s12866-021-02147-9
pmc: PMC7983228
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

86

Références

Emerg Infect Dis. 2001 Mar-Apr;7(2):342-7
pubmed: 11294737
Clin Infect Dis. 2010 Mar 1;50(5):625-63
pubmed: 20175247
Urology. 1985 Oct;26(4):369-75
pubmed: 3931323
Am J Infect Control. 2018 Dec;46(12):e81-e90
pubmed: 30174256
N Engl J Med. 1957 Mar 21;256(12):556-7
pubmed: 13419041
N Engl J Med. 1980 Aug 7;303(6):316-8
pubmed: 6991947
Am J Surg. 1999 Apr;177(4):287-90
pubmed: 10326844
Antimicrob Agents Chemother. 2002 Apr;46(4):1128-31
pubmed: 11897606
J Hosp Infect. 1996 Feb;32(2):105-15
pubmed: 8666761
Infect Control Hosp Epidemiol. 2007 Dec;28(12):1367-73
pubmed: 17994517
J Clin Microbiol. 1995 Sep;33(9):2233-9
pubmed: 7494007
Eur J Clin Microbiol Infect Dis. 2001 Apr;20(4):260-2
pubmed: 11399016
Mayo Clin Proc. 1999 Feb;74(2):131-6
pubmed: 10069349
Am J Infect Control. 2015 Mar 1;43(3):206-21
pubmed: 25575913
Br J Urol. 1973 Dec;45(6):678-83
pubmed: 4204547
J Urol. 1972 Nov;108(5):719-21
pubmed: 5081705
JAMA. 1984 Oct 19;252(15):2028-30
pubmed: 6481909
Infect Control Hosp Epidemiol. 2014 May;35(5):464-79
pubmed: 24709715
Infect Control. 1981 Sep-Oct;2(5):380-6
pubmed: 6795141
J Urol. 1983 Dec;130(6):1096-9
pubmed: 6358531
Infect Control Hosp Epidemiol. 2010 Apr;31(4):319-26
pubmed: 20156062
N Engl J Med. 1974 Aug 1;291(5):215-9
pubmed: 4834750
J Med Eng Technol. 2015;39(8):459-70
pubmed: 26383168
Intensive Care Med. 2007 Apr;33(4):726-9
pubmed: 17294169

Auteurs

Claire Aumeran (C)

Infection Control Department, 3IHP, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France. caumeran@chu-clermontferrand.fr.
Université Clermont Auvergne, UMR CNRS 6023 'Laboratoire Microorganismes: Génome Environnement (LMGE)', F-63000, Clermont-Ferrand, France. caumeran@chu-clermontferrand.fr.
Service d'Hygiène Hospitalière, Hôpital Gabriel Montpied, 58 Rue Montalembert, 63003, Clermont-Ferrand Cedex 1, France. caumeran@chu-clermontferrand.fr.

Benoit Mottet-Auselo (B)

Infection Control Department, 3IHP, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.

Christiane Forestier (C)

Université Clermont Auvergne, UMR CNRS 6023 'Laboratoire Microorganismes: Génome Environnement (LMGE)', F-63000, Clermont-Ferrand, France.

Paul-Alain Nana (PA)

Université Clermont Auvergne, UMR CNRS 6023 'Laboratoire Microorganismes: Génome Environnement (LMGE)', F-63000, Clermont-Ferrand, France.

Claire Hennequin (C)

Université Clermont Auvergne, UMR CNRS 6023 'Laboratoire Microorganismes: Génome Environnement (LMGE)', F-63000, Clermont-Ferrand, France.
Bacteriology Department, 3IHP, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.

Frédéric Robin (F)

Bacteriology Department, 3IHP, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.
Université Clermont Auvergne, UMR INSERM 1071 'Laboratoire Microbe intestin inflammation et Susceptibilité de l'Hôte (M2ISH)', USC INRA2018, F-63000, Clermont-Ferrand, France.
Laboratoire associé Résistance des Entérobactéries BLSE/Céphalosporinases, Centre National de Référence Résistance aux Antibiotiques, Clermont-Ferrand, France.

Bertrand Souweine (B)

Université Clermont Auvergne, UMR CNRS 6023 'Laboratoire Microorganismes: Génome Environnement (LMGE)', F-63000, Clermont-Ferrand, France.
Intensive Care Medicine, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.

Ousmane Traoré (O)

Infection Control Department, 3IHP, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.
Université Clermont Auvergne, UMR CNRS 6023 'Laboratoire Microorganismes: Génome Environnement (LMGE)', F-63000, Clermont-Ferrand, France.

Alexandre Lautrette (A)

Université Clermont Auvergne, UMR CNRS 6023 'Laboratoire Microorganismes: Génome Environnement (LMGE)', F-63000, Clermont-Ferrand, France.
Intensive Care Medicine, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH